MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- BIOCON - TEVA PHARMA (Israel)
BIOCON vs TEVA PHARMA (Israel) - Comparison Results
BIOCON Change
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 BIOCON  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| BIOCON Mar-19 |
TEVA PHARMA Dec-13 |
BIOCON / TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 707 | 3,145 | - | |
| Low | Rs | 554 | 2,732 | - | |
| Sales per share (Unadj.) | Rs | 91.9 | 1,804.8 | - | |
| Earnings per share (Unadj.) | Rs | 16.7 | 112.7 | - | |
| Cash flow per share (Unadj.) | Rs | 24.2 | 258.6 | - | |
| Dividends per share (Unadj.) | Rs | 1.00 | 98.70 | - | |
| Dividend yield (eoy) | % | 0.2 | 3.4 | 4.7% | |
| Book value per share (Unadj.) | Rs | 101.6 | 2,004.8 | - | |
| Shares outstanding (eoy) | m | 600.00 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 6.9 | 1.6 | 421.4% | |
| Avg P/E ratio | x | 37.7 | 26.1 | 144.8% | |
| P/CF ratio (eoy) | x | 26.1 | 11.4 | 229.6% | |
| Price / Book Value ratio | x | 6.2 | 1.5 | 423.3% | |
| Dividend payout | % | 6.0 | 87.5 | 6.8% | |
| Avg Mkt Cap | Rs m | 378,330 | 2,491,644 | 15.2% | |
| No. of employees | `000 | 6.1 | 44.9 | 13.6% | |
| Total wages/salary | Rs m | 11,653 | 0 | - | |
| Avg. sales/employee | Rs Th | 8,994.3 | 34,051.8 | 26.4% | |
| Avg. wages/employee | Rs Th | 1,900.7 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,635.3 | 2,127.2 | 76.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 55,144 | 1,530,457 | 3.6% | |
| Other income | Rs m | 1,444 | 0 | - | |
| Total revenues | Rs m | 56,588 | 1,530,457 | 3.7% | |
| Gross profit | Rs m | 15,883 | 419,116 | 3.8% | |
| Depreciation | Rs m | 4,478 | 123,708 | 3.6% | |
| Interest | Rs m | 709 | 30,061 | 2.4% | |
| Profit before tax | Rs m | 12,140 | 265,347 | 4.6% | |
| Minority Interest | Rs m | 9 | 1,205 | 0.7% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -174,186 | 0.0% | |
| Tax | Rs m | 2,123 | -3,240 | -65.5% | |
| Profit after tax | Rs m | 10,026 | 95,606 | 10.5% | |
| Gross profit margin | % | 28.8 | 27.4 | 105.2% | |
| Effective tax rate | % | 17.5 | -1.2 | -1,432.4% | |
| Net profit margin | % | 18.2 | 6.2 | 291.0% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 48,228 | 1,033,665 | 4.7% | |
| Current liabilities | Rs m | 30,376 | 901,443 | 3.4% | |
| Net working cap to sales | % | 32.4 | 8.6 | 374.7% | |
| Current ratio | x | 1.6 | 1.1 | 138.5% | |
| Inventory Days | Days | 68 | 91 | 75.2% | |
| Debtors Days | Days | 86 | 96 | 89.1% | |
| Net fixed assets | Rs m | 64,130 | 499,881 | 12.8% | |
| Share capital | Rs m | 3,000 | 3,767 | 79.6% | |
| Net worth | Rs m | 60,980 | 1,700,047 | 3.6% | |
| Long term debt | Rs m | 15,766 | 782,557 | 2.0% | |
| Total assets | Rs m | 121,924 | 3,497,584 | 3.5% | |
| Interest coverage | x | 18.1 | 9.8 | 184.4% | |
| Debt to equity ratio | x | 0.3 | 0.5 | 56.2% | |
| Sales to assets ratio | x | 0.5 | 0.4 | 103.4% | |
| Return on assets | % | 8.8 | 3.6 | 245.1% | |
| Return on equity | % | 16.4 | 5.6 | 292.4% | |
| Return on capital | % | 16.8 | 4.9 | 339.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 11,546 | 243,876 | 4.7% | |
| From Investments | Rs m | -7,138 | -86,415 | 8.3% | |
| From Financial Activity | Rs m | -2,417 | -292,545 | 0.8% | |
| Net Cashflow | Rs m | 2,103 | -135,085 | -1.6% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 75.34 Rs / USD
Compare BIOCON With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare BIOCON With: GSK PHARMA FRESENIUS KABI ONCO. DR. DATSONS LABS FDC ELDER PHARMA
Today's Market
Sensex Opens Marginally Lower; Power Grid Jumps 4%(09:30 am)
Asian stock markets are trading on a mixed note today. The Nikkei is trading down by 0.8% while the Hang Seng is up 1%. The Shanghai Composite is trading higher by 0.1%.
Related Views On News
BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)
Jan 25, 2021 | Updated on Jan 25, 2021For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)
Oct 29, 2020 | Updated on Oct 29, 2020For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)
Apr 20, 2021In this video I tell you the three Nifty ETFs I think are the best.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
More
